35 results about "Vaccine Immunogenicity" patented technology

The invention relates to the technical field of inactivated vaccines for poultry, and discloses a bivalent inactivated vaccine composite adjuvant for poultry, which comprises the following components in percentage by mass: 5-10% of nano-scale chitosan microspheres with the particle size range of 50-100 nanometers; the lipidosome is prepared from phospholipid and cholesterol according to the molar ratio of 3: 1, and the mass fraction is 3%-6%; a cell factor interleukin-2 (IL-2) with a concentration of 10 to 20 [mu] g / mL; the mass fraction of the sodium alginate solution is 1%-3%. According to the preparation and application of the bivalent inactivated vaccine composite adjuvant for poultry, the nanoscale chitosan microspheres, the lipidosome and the like are effectively combined through an innovative formula, the nanoscale chitosan microspheres can promote antigen uptake, the lipidosome realizes slow release of the antigen, meanwhile, the cell factor IL-2 activates immune cells, humoral immunity and cellular immunity are comprehensively enhanced, and the immune effect of the bivalent inactivated vaccine composite adjuvant for poultry is improved. The immunogenicity of the vaccine is greatly improved, the organism can be induced to generate higher-level antibodies and stronger cellular immunity, and a defense line is built for the health of poultry.

The invention discloses an EB (Epstein-Barr) virus antigen with chimeric design and application thereof. The EB virus chimeric antigen provided by the invention is reasonably designed on the basis of structural biology, gL, gH and gp42 proteins of the EB virus are connected through a linker, and the chimeric designed antigen stably presents antigen epitopes of the three proteins at the same time, so that the production amplification process and quality control can be simplified while the vaccine immunogenicity is improved. The EB virus chimeric antigen can be used independently or in combination with other antigens, has high immunogenicity when being used as a vaccine or a vaccine component, can induce an immunized animal to generate a high-level neutralizing antibody, can be used for preparing a vaccine for preventing or treating EB virus infection, and can also be used as a reagent for detecting EB virus.

The present application relates to the technical field of veterinary biological products, and particularly provides a porcine circovirus type 3 (PCV3) Cap protein and a related product thereof. The PCV3 Cap protein is an NLS region 8-16aa truncated Cap protein. The amino acid sequence of the Cap protein is as shown in SEQ ID NO: 2. The present application further provides a PCV3 virus-like particle antigen, which is the PCV3 Cap protein. The Cap protein is expressed at a higher level. A vaccine prepared from the antigen exhibits strong immunogenicity and provides excellent protective efficacy.

The invention provides a human immune organoid system for vaccine immunogenicity evaluation and a preparation method thereof, and relates to the technical field of biological titer detection, and the technical key points are as follows: by constructing a highly bionic engineered human immune organoid system and combining multi-omics analysis, the human immune organoid system can be used for evaluating the immunogenicity of a vaccine. The method comprehensively characterizes the process that mRNA vaccine stimulates immune organoid to induce GC formation and B cell maturation differentiation, constructs an mRNA vaccine immunogenicity evaluation system based on human immune organoid, and accurately and efficiently performs vaccine preclinical evaluation, so as to solve the problem that design optimization and screening detection of mRNA vaccines are lack of a suitable in-vitro model, and improve the evaluation accuracy of mRNA vaccine immunogenicity. And a new thought and a technical platform are provided for mRNA vaccine development.

The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising a pathogen recognition receptor agonist.

The invention discloses a group A streptococcus mRNA (messenger Ribonucleic Acid) vaccine and application thereof, and relates to the technical field of biological medicines, in particular to the group A streptococcus mRNA vaccine and application thereof. The mRNA for coding the group A streptococcus antigen contains an open reading frame; the nucleotide sequence of the coding open reading frame is M12 <-N > + M1 <-N > + M4 <-N >, and is as shown in SEQ ID NO. 1; the antigen sequence of the group A streptococcus mRNA vaccine has no homology with human tissue protein through blastp comparison; the mRNA vaccine has strong immunogenicity, can effectively inhibit three GAS serotypes, and covers main GAS epidemic strains in China at present; the mRNA vaccine has the advantages of high efficiency, broad spectrum, high safety and simplicity and convenience in use, and is easy to popularize and use.

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.

Pseudoviruses expressing the SARS-CoV-2 S protein are provided herein. Assays using these pseudoviruses to evaluate the immunogenicity of biological samples against the SARS-CoV-2 virus or variants thereof are also provided herein. Methods for evaluating the immunogenicity of COVID-19 vaccines using these assays are also provided herein. Pseudoviruses encoding (i) the SARS-CoV-2 spike (S) protein; (ii) one or more of the Rev, Tat, Gag, and Pol proteins; and (iii) a reporter protein are provided herein.

An improved assay is required to measure the immunogenicity of vaccines while overcoming some limitations of current immunogenic biomarkers. Disclosed herein is an assay for measuring inhibition of binding between a SARS-CoV-2 spike (S) glycoprotein and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of a COVID-19 vaccine.

The invention relates to the technical field of vaccine preparations, in particular to a preparation method and application of a pseudomonas aeruginosa DNA vaccine combined with a CpG-ODN adjuvant. The invention discloses a pseudomonas aeruginosa DNA vaccine combined with a CpG-ODN adjuvant. The pseudomonas aeruginosa DNA vaccine is prepared from the following raw materials: CpG oligonucleotide and a pseudomonas aeruginosa DNA vaccine. According to the technical scheme, the technical problems that an existing DNA vaccine is insufficient in immunogenicity, and effective immune response is difficult to induce can be solved. A synergistic effect is generated between the adjuvant and the vaccine, the secretion of cell factors is promoted, the antibody titer is improved, and the immune response effect is improved in the aspect of inducing the immune response of Th1 / Th2 / Th17 mixed cells. According to the technical scheme, a small-dose adjuvant is innovatively combined to enhance the immunogenicity of the vaccine, the immune efficacy of the vaccine and the safety of the vaccine are improved, and the novel DNA vaccine is simple in preparation method, remarkable in effect and ideal in application and popularization prospect.

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Here, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene (GPC) of the laboratory CCHFV strain CCHFV-IbAr 10200 (CCHFV-M10200). Increasing the dose of CCHFV-M 10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant, heterologous CCHFV-Afg09-2990 strain. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 GPC expressing DNA vaccine (CCHFV-M Afgog). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.

The invention relates to an application of a tripterine nano particle in preparation of an immunologic adjuvant. The tripterine nano particle comprises a nano aggregate and a polymer shell, wherein the nano aggregate is formed by self-assembly of tripterine or medicinal salt of the tripterine, and the outer surface of the nano aggregate is coated with the polymer shell. The invention develops a brand-new immunologic adjuvant strategy, namely, a product obtained by coating a nano aggregate formed by self-assembly of the tripterine or medicinal salt thereof with a polymer, and under the condition of using the same dosage, compared with tripterine free molecules or nanoparticles not coated with the polymer, the tripterine free molecules or the nanoparticles not coated with the polymer have better immunologic adjuvant effect. The product has a more remarkable effect of enhancing the immunogenicity of the vaccine. Therefore, the product can be applied as an immunologic adjuvant. Meanwhile, the preparation method of the product is simple and mild in condition, green and environment-friendly, low in cost, free of special reaction equipment and easy to popularize and apply.

Provided are a truncated respiratory syncytial virus (RSV) F protein or a variant thereof, and a fusion protein comprising the truncated RSV F protein or the variant thereof, and a truncated human metapneumovirus (hMPV) F protein or a variant thereof. Also provided is uses of the fusion protein and a vaccine, immunogenic composition, kit, and pharmaceutical composition comprising the fusion protein in prevention and / or treatment of RSV and / or hMPV infections or diseases and / or symptoms caused by RSV and / or hMPV infections.

The application discloses a porcine epidemic diarrhea virus and porcine delta coronavirus double vaccine and a preparation method thereof. The double attenuated live vaccine is prepared from a PEDV G2a genotype weak strain CH / HBXT-P240 / 2018 (the preservation number is CGMCC NO:45213), a PEDV G2b genotype weak strain CH / HNPJ-P240 / 2017 (the preservation number is CGMCC NO:5212) and a PDCoV weak strain CH / XJYN-P240 / 2016 (the preservation number is CGMCC NO:45211) as seed viruses for vaccine preparation, virus proliferation is carried out in combination with a cell suspension culture process, and the double vaccine is prepared through vaccine preparation and freeze-drying. The vaccine has strong immunogenicity, good cross-protection effect and high safety, can prevent piglet diarrhea caused by two kinds of coronaviruses at the same time, and is suitable for immune prevention and control in large-scale farms.

The application discloses a CpG oligodeoxynucleotide, which has a nucleotide sequence as shown in any one of SEQ ID NO. 1-8; or a nucleotide sequence with one or more nucleotides substituted or added to the nucleotide sequence as shown in SEQ ID NO. 8 and with the same function. The application has the beneficial effect that animal experiments prove that a vaccine containing the CpG oligodeoxynucleotide has a higher IgG binding antibody level in the serum GMT detection result of mice 14 days after the second immunization, is obviously better than the negative control and the positive control, and the effect is related to the specific base sequence of the CpG oligodeoxynucleotide. The above results prove that the CpG oligodeoxynucleotide can obviously enhance the immunogenicity of the vaccine, reduce the number of immunization needles, reduce the antigen usage, and has a better vaccine adjuvant effect when applied to the preparation of the vaccine.

Provided is a Coxsackievirus A6 (CVA6) strain CVA6-KM-J33 and use thereof, and belongs to the technical field of biomedicine. The present invention provides a CVA6 strain CVA6-KM-J33, which belongs to a CVA6 virus. In the present invention, the strain CVA6-KM-J33 is susceptible to KMB17 cells and can achieve a relatively high titer. The strain has strong virulence, high pathogenicity and lethality to suckling mice, and desirable immunogenicity, and is a highly effective virus strain for CVA6 vaccine development. This strain can be used for immunogenicity evaluation or protective evaluation of CVA6 vaccine to improve the accuracy and reproducibility of vaccine immunogenicity evaluation. This strain can also be used to prepare animal models of Coxsackievirus (CV) infection, and exhibits desirable application prospects.

Provided herein is a pseudovirus that expresses an SARS-CoV-2S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against the SARS-CoV-2 virus or a variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assay.

The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen recognition receptor agonist.

The invention provides a nucleic acid molecule related to HIV-1 (human immunodeficiency virus-1), a fusion protein and a preparation method and application thereof, and belongs to the technical field of biological medicine.The mRNA vaccine provided by the invention encodes the fusion protein, and the fusion protein is any one of a Ub-Gag fusion protein and a Ub-Pol fusion protein, the protein can efficiently induce HIV-1 specific cytotoxic T lymphocyte (CTL) response, so that the capability of eliminating latent viruses of an organism is enhanced, and the defects that an existing HIV-1 vaccine is insufficient in immunogenicity and immune escape is likely to occur are effectively overcome.

The invention discloses a preparation method of a PEDV vaccine, and relates to the technical field of vaccine preparation. The method comprises the following steps: S1, selecting a PEDV strain and virus propagation, selecting a corresponding PEDV strain according to a designed screening condition and a set screening algorithm, measuring and calculating the effects of a vaccine under different immune strategies through a virus propagation algorithm, designing a corresponding vaccine dosage optimization algorithm, and determining the vaccine dosage according to the relationship between the vaccine immunogenicity and the immune protection effect; optimizing the dose ratio of the vaccine by using regression analysis; and S2, obtaining and culturing a virus strain, and separating the PEDV from the infected pig. According to the method, multiple algorithm designs are introduced, quantification, prediction and optimization of key links are realized, the comprehensive beneficial effects of accurate matching, process optimization, efficiency improvement, risk controllability, cost reduction, development acceleration and the like are brought, and research, development and production of PEDV vaccines are promoted to enter a more scientific, intelligent and efficient new stage.

The present disclosure relates to lipid-based delivery vehicles for mRNA vaccines, which include a lysophosphatidylcholine (LPC) compound for enhancing vaccine immunogenicity. The present disclosure also relates to methods for use of the mRNA vaccines.

The invention discloses gE virus-like nanoparticles containing gI Th epitopes as well as a preparation method and application of the gE virus-like nanoparticles, and relates to the technical field of biomedicine. The gE virus-like nanoparticle is formed by self-assembling a plurality of monomers; the monomer comprises VZV gE and a VZV gI polypeptide containing a Th epitope. The gE virus-like nanoparticles can be applied to VZV vaccines, and the technical problems that the gE immunogenicity is weak and the vaccine side reaction is serious in the vaccine preparation in the prior art are solved. The gE virus-like nanoparticles provided by the invention significantly enhance the immunogenicity of gE, and the preparation method of the nanoparticles is simple. Compared with the Xinanlietai, the vaccine provided by the invention has the advantages of better immunogenicity, less immunopotentiator dosage and lower clinical side reaction, can induce gI specific CMI reaction, and is beneficial to further improvement of the effectiveness of the vaccine. The gE virus-like nanoparticle containing the gI epitope has good clinical application potential.

Provided are a truncated respiratory syncytial virus (RSV) F protein or a variant thereof, and a fusion protein comprising the same and a truncated body of human metapneumovirus (hMPV) F protein or a variant of the truncated body. Also provided are uses of the fusion protein as well as vaccines, immunogenic compositions, kits and pharmaceutical compositions comprising the same for the prevention and / or treatment of RSV and / or hMPV infection or diseases and / or symptoms caused by RSV and / or hMPV infection.

Provided are an epitope or epitope peptide of a respiratory syncytial virus (RSV) F protein, and a fusion protein containing the epitope or epitope peptide and a truncated F protein of human metapneumovirus (hMPV) or a variant of the truncated protein. Further provided are the use of the fusion protein and of a vaccine, an immunogenic composition, a kit, and a pharmaceutical composition containing same in preventing and / or treating RSV and / or hMPV infection or diseases and / or symptoms caused by RSV and / or hMPV infection.

The invention discloses gE nanoparticles containing gI epitopes as well as a preparation method and application of the gE nanoparticles, and relates to the technical field of biomedicine, and the gE nanoparticles are formed by polymerizing a plurality of monomers; the monomers include VZVgE and a VZV gI polypeptide containing a Th epitope. The gE nano-particles can be applied to VZV vaccines, and the technical problems that the gE immunogenicity is weak and the vaccine side reaction is serious in vaccine preparation in the prior art are solved. Compared with the traditional Chinese medicine gE nano-particle, the VZV vaccine taking the gE nano-particle as the antigen has the advantages that the variety and the dosage of an immunopotentiator are less, the immunogenicity of the vaccine is equivalent to that of the traditional Chinese medicine gE nano-particle, and the clinical side reaction of the vaccine is lower; in addition, the gE nanoparticle vaccine not only can induce a gE specific CMI reaction, but also can induce a high-level gI specific CMI reaction, so that the effectiveness of the vaccine is further improved. In conclusion, the gE nanoparticles have good clinical application potential.

The present invention discloses tumor antigen peptides targeting CD73, vaccines, and preparation methods and applications thereof. Based on the amino acid sequence of CD73 protein, the present invention combines MHC typing to synthesize antigen peptides for targeted and immunotherapy of solid tumors, including drugs and vaccines for the preparation of new antigen-reactive T cell therapy and engineered T cell therapy. The tumor peptide vaccine targeting CD73 provided by the present invention has good immunogenicity and strong targeted killing ability of induced antigen-specific T cells.

The invention discloses a method for preparing a foot-and-mouth disease subunit recombinant protein vaccine and evaluating immune efficacy of the foot-and-mouth disease subunit recombinant protein vaccine. By optimizing the prokaryotic expression process of the O-type FMDV VP1 protein, the obtained recombinant VP1 protein is mainly expressed in the form of an inclusion body; an adjuvant compatibility scheme adaptive to the recombinant protein is further designed, so that the immunogenicity of the vaccine is enhanced; meanwhile, a mouse-based immune efficacy evaluation method is established, and low-cost and short-period vaccine efficacy evaluation is realized by detecting the immunogenicity of the VP1 protein. The method effectively solves the problems that the prokaryotic expression VP1 subunit vaccine is insufficient in immune efficacy and high in evaluation cost, and provides efficient and practical technical support for research, development and industrialization of foot-and-mouth disease subunit recombinant protein vaccines.

The invention discloses a circular RNA vaccine based on a vasoactive intestinal peptide delivery system and application of the circular RNA vaccine, and relates to the field of RNA vaccines. Comprising vasoactive intestinal peptide VIP serving as a delivery carrier and circular RNA for coding a respiratory syncytial virus RSVpreF antigen, and the vasoactive intestinal peptide VIP and the circular RNA form a compound through non-covalent linkage; the vasoactive intestinal peptide VIP is a VIP-EGFP-N fusion protein. According to the invention, the function of the VIP as a high-efficiency cell-penetrating peptide is explored and verified for the first time, and the VIP is combined with a circular RNA molecule of a coding RSV key antigen protein preF to construct a safe, stable and high-efficiency RSV vaccine, so that the technical bottlenecks of poor stability of the existing mRNA vaccine, complex and low-efficiency LNP delivery system, insufficient immunogenicity or poor safety of the traditional RSV vaccine and the like are solved.

Assays for measuring the inhibition of the binding between the SARS-CoV-2 spike (S) glycoprotein and hACE2 are disclosed herein. Methods of using this assay to evaluate the effectiveness of COVID-19 vaccines are also provided herein. A novel biomarker of COVID-19 vaccine immunogenicity, inhibition of SARS-CoV-2 spike (S) protein binding to the hACE2 receptor, is provided herein. This assay provides a rapid high-throughput option for evaluating vaccine immunogenicity. Together with other clinical biomarkers, this can provide valuable insights into the correlations of immune escape and protection and enable vaccine development against emerging COVID-19 variants.

The present invention relates to a lipid for enhancing the immunogenicity of mRNA / LNP vaccines and, more specifically, to a lipid nanoparticle comprising a lipid that includes propionate, butyrate, or both, and a drug delivery carrier utilizing same. The lipid nanoparticle according to the present invention can significantly enhance the immunogenicity of a nucleic acid-based vaccine contained therein.